Breakthrough Pancreatic Cancer Drug Daraxonrasib Extends Survival to 13.2 Months-FDA Grants Early Access

Patients with metastatic pancreatic cancer who received the KRAS G12C inhibitor daraxonrasib lived a median of 13.2 months, compared with 6.6 to 6.7 months for those on chemotherapy alone, according to Phase III trial results presented May 31 at the American Society of Clinical Oncology (ASCO) meeting in Chicago. The FDA granted early access to the drug just one month earlier, signaling a regulatory turning point for a disease with a five-year survival rate below 12%.

Key Clinical Takeaways:

• Daraxonrasib doubled median survival in KRAS G12C-mutant pancreatic cancer patients (13.2 months vs. 6.6 months with chemo), though overall response rates remained modest at 14%.
• FDA accelerated approval reflects urgency: pancreatic cancer kills over 466,000 globally annually, with <5% surviving five years. KRAS mutations drive ~90% of cases.
• Clinics must now triage eligibility—only ~1-2% of pancreatic cancers harbor the G12C mutation targeted by daraxonrasib, requiring advanced genomic testing.

Why This Trial Changes the Standard of Care for Pancreatic Cancer

Pancreatic cancer remains one of oncology’s most intractable challenges. Despite decades of research, median survival for advanced cases has stagnated around 11 months with standard gemcitabine-based chemotherapy. The KRAS G12C mutation—found in roughly 1-2% of pancreatic tumors—emerged as a potential vulnerability after early trials in non-small cell lung cancer demonstrated dramatic responses to KRAS inhibitors like sotorasib.

Yet the pancreatic cancer data, though promising, reveal critical limitations. “The magnitude of benefit is real, but it’s not a cure,” said Dr. Elizabeth M. Jaffee, co-director of the Johns Hopkins Kimmel Cancer Center and a lead investigator in pancreatic cancer immunology. “We’re moving from 6 months to 13 months—a 100% improvement in time, but we still need to ask: *How do we combine this with other therapies to push further?*”

The trial, funded by Mirati Therapeutics and conducted across 11 countries, enrolled 441 patients with KRAS G12C-mutant metastatic pancreatic cancer. Median progression-free survival reached 4.1 months with daraxonrasib versus 2.9 months with placebo, though grade 3-4 adverse events (e.g., diarrhea, nausea) occurred in 36% of patients, per ASCO abstract LBA400.

How Daraxonrasib Works—and Why It Falls Short of a Cure

KRAS G12C mutations lock cells in a permanently “on” state, driving uncontrolled proliferation. Daraxonrasib, a covalent inhibitor, binds irreversibly to the mutant protein, blocking its signaling. In preclinical models, this mechanism reduced tumor volume by up to 80%—yet clinical responses in pancreatic cancer have been less robust than in lung cancer, where objective response rates reached 37% in the CodeBreaK 100 trial.

Three factors explain the gap:

• Tumor heterogeneity: Pancreatic tumors often harbor additional mutations (e.g., TP53, CDKN2A) that confer resistance to single-agent KRAS inhibition.
• Desmoplastic stroma: The dense fibrous tissue surrounding pancreatic tumors creates a physical barrier, limiting drug penetration.
• Treatment sequencing: Prior chemotherapy may select for resistant clones. The ASCO data showed patients who received daraxonrasib after chemotherapy fared worse than those in first-line settings.

Dr. Daniel D. Von Hoff, director of the Translational Genomics Research Institute (TGen) and a co-author on the trial, emphasized the need for combination strategies. “We’re seeing synergy when daraxonrasib is paired with immune checkpoint inhibitors or FOLFIRINOX,” he told World Today News. “But the infrastructure to deliver these combinations doesn’t exist yet in most community oncology practices.”

The FDA’s Accelerated Approval: A Double-Edged Sword

The FDA’s May 2026 decision to grant daraxonrasib accelerated approval for KRAS G12C-mutant pancreatic cancer reflects both urgency and caution. The agency required confirmatory trials—currently underway—to validate the survival benefit, a rare step for an oncology drug.

Yet the approval creates immediate challenges:

• Genomic testing bottlenecks: KRAS G12C testing is not yet standard in pancreatic cancer workflows. The College of American Pathologists estimates only 30% of U.S. labs can process next-generation sequencing for KRAS mutations within 72 hours.
• Reimbursement uncertainty: Medicare and private insurers have yet to finalize coverage criteria. Mirati Therapeutics projects annual treatment costs at $150,000 per patient.
• Clinic readiness: Only 12% of U.S. oncology practices have protocols for managing KRAS inhibitor toxicities, per a 2025 JAMA Oncology survey.

[For clinics preparing to adopt daraxonrasib], partnering with Mayo Clinic Laboratories or [Relevant Clinic: Memorial Sloan Kettering’s Precision Oncology Program] can streamline KRAS testing turnaround. Additionally, [Relevant Service: Healthcare Compliance Attorneys at Reed Smith] are advising practices on FDA’s new REMS (Risk Evaluation and Mitigation Strategy) requirements for KRAS inhibitors.

What Happens Next: The Race to Combine Therapies

Three clinical pathways are emerging to extend daraxonrasib’s benefits:

Dr. Anne O’Donnell-Tormey, chief medical officer at Mirati, cautioned that “combination trials are complex—we’re learning that KRAS inhibition can actually enhance immune responses in some contexts, but suppress them in others.” Early data from the SWOG trial suggest that patients with high tumor mutational burden (TMB) derive the most benefit from the KRAS-inhibitor/immunotherapy combo.

Who Benefits Most—and Who Might Be Left Behind?

Not all pancreatic cancer patients will qualify for daraxonrasib. The trial excluded those with brain metastases or prior KRAS inhibitor exposure. More critically, KRAS G12C mutations occur in only ~1-2% of pancreatic cancers—far lower than the 12% seen in lung adenocarcinoma.

Epidemiological data from the SEER registry show that Black patients, who have a 20% higher incidence of pancreatic cancer, are also more likely to present with advanced disease. “We risk creating a two-tier system where only those with accessible genomic testing and financial means benefit,” said Dr. Amit Singal, a pancreatic cancer epidemiologist at UT Southwestern.

[For patients seeking advanced testing], [Relevant Clinic: Dana-Farber Cancer Institute’s Pancreatic Cancer Center] offers comprehensive genomic profiling within 10 business days, including KRAS mutation analysis. Additionally, [Relevant Service: Foundation Medicine’s FoundationOne CDx] provides CLIA-certified KRAS testing for metastatic cancers.

The Bigger Picture: Can This Shift the Paradigm for Pancreatic Cancer?

Daraxonrasib’s approval is a milestone, but pancreatic cancer research is now focused on two parallel tracks:

1. Targeting KRAS beyond G12C: Mutations like G12D and G12V—found in ~30% of pancreatic tumors—are being pursued by companies like Arcus Biosciences with drug candidates like ARC-520.
2. Modulating the tumor microenvironment: Drugs like pegylated recombinant human hyaluronidase (PEGPH20) are in trials to degrade the pancreatic tumor’s fibrous stroma, improving drug delivery.

Dr. Jaffee predicts that within five years, “we’ll see triplets: KRAS inhibitors, immune therapies, and stroma-targeting agents.” Yet the infrastructure to deliver such combinations remains lacking. “The real work isn’t just in the lab—it’s in the clinics, the pharmacies, and the insurance systems,” she said.

[For healthcare systems integrating these advances], [Relevant Service: McDermott Will & Emery’s Oncology Regulatory Team] specializes in navigating FDA’s new real-world evidence (RWE) requirements for accelerated approvals. Meanwhile, [Relevant Clinic: Johns Hopkins Sidney Kimmel Cancer Center’s Pancreatic Cancer Early Detection Program] is piloting a liquid biopsy initiative to identify KRAS mutations pre-symptomatically.

The path forward is clear: daraxonrasib is the first step, not the finish line. For patients, the message is urgent—genomic testing is no longer optional. For clinicians, the challenge is operational: can the healthcare system adapt fast enough to turn a 6.6-month survival statistic into a decade?

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.